Werner syndrome presenting as early-onset diabetes: A case report

Xiaoli Wang1*, Sinuo Liu2, Fengye Qin1, Qian Liu1, Qiuyue Wang1

1Department of Endocrinology and Metabolism, Institute of Endocrinology, NHC Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The First Affiliated Hospital of China Medical University, Shenyang, China, and 2Department of Endocrinology, General Hospital of Northern Theater Command of Chinese People’s Liberation Army, Shenyang, China

Keywords
Diabetes mellitus, Werner syndrome, WRN gene

*Correspondence
Xiaoli Wang
Tel: +86-180-4009-6515
Fax: +86-024-83283073
E-mail address: wittlepear@163.com

J Diabetes Investig 2022; 13: 592–598
doi: 10.1111/jdi.13682

INTRODUCTION
Werner syndrome (WS; OMIM #277700) is a rare autosomal recessive premature progeroid syndrome characterized by early onset of age-related diseases, such as cataracts, atherosclerosis, type 2 diabetes, osteoporosis and malignancies1,2. The prevalence of diabetes is exceptionally high (55–71%) in WS, and it usually appears at 30–40 years-of-age, marked by accumulated visceral fat, insulin resistance with low body mass index2,3. WS’s clinical criteria are now available at the International Registry of Werner Syndrome (www.wernersyndrome.org), and new diagnostic criteria have been revised according to clinical experience with Japanese cases of WS4. However, confirmation of diagnosis still requires WRN gene testing.

Here, we report a young woman with diabetes. The early onset age (18 years) of diabetes with very low body mass index (15.43 kg/m²), insulin resistance, negative antibodies of diabetes and early onset of cataracts. Genome sequencing and reverse transcription polymerase chain reaction confirm the diagnosis. A novel heterozygous splice-site mutation in the WRN gene (c.1270-2A>T) was identified. The present case reminds clinicians that when young diabetes patients are encountered, if they are accompanied by premature aging, attention should be paid to identifying the possibility of Werner syndrome based on diagnostic criteria.

CASE REPORT
An 18-year-old female patient presented with hyperglycemia for 2 months and was admitted to the Department of Endocrinology and Metabolism, First Affiliated Hospital of China Medical University, Shenyang, China. She has no apparent symptoms of thirst, polydipsia, polyphagia and polyuria. Before she came to our hospital, she was treated for type 1 diabetes with insulin for 1 week. Her parents were healthy and were not consanguineous. Her grandfather had type 2 diabetes mellitus. Her older brother had a history of cataracts since the age of 2 years.

The patient appeared like she was aged in her 30s and showed the following features: height 163 cm; weight 41 kg; body mass index 15.43 kg/m²; heart rate 74 b.p.m.; blood pressure 115/68 mmHg; and a bird-like face, slim limbs, dry hair, and dry and atrophic skin (Figure 1). Ophthalmic examination showed upper eyelid trichiasis, rough corneal epithelium, lens posterior capsule opacity and vitreous opacity. Her voice was normal.

Laboratory examinations showed the presence of hypertriglyceridemia, insulin resistance with elevated blood glucose level and hemoglobin A1c, normal levels of glutamic acid decarboxylase and insulin autoantibody, normal level of plasma lactic acid, negative urine ketone and decreased level of sex hormone-binding globulin (Table 1).

Abdominal color Doppler ultrasound showed fatty liver. The color Doppler ultrasound of the carotid artery showed that the carotid intima-media thickness was 0.6 mm on the left and 0.7 mm on the right. Audiological examinations did not show any abnormalities. Dual-energy X-ray absorptiometry showed normal bone density in the lumbar vertebrae (Z = 0.8). X-ray of her feet did not discover Achilles tendon calcification.
Blood samples were collected from the patient and her parents. Genomic deoxyribonucleic acid (DNA) was extracted from the peripheral blood using a Blood DNA Kit (CWE9600, CoWin Biosciences Inc., Beijing, China). IDT xGen Exome Research Panel v1.0 (Integrated DNA Technologies, Inc., Coralville, IA, USA) was used for exon trapping. Illumina NovaSeq (San Diego, CA, USA) was used for high-throughput sequencing. Emphasis was laid on the analysis of all known genes (total 195) involved in diabetes mellitus. Two heterozygous variants found in the \( \text{WRN} \) gene were believed to be responsible for the prominent phenotype of the patient. The first variants was NM_000553.4 c.3020delG from the paternal origin, can be classified as pathogenic according to American College of Medical Genetics and Genomics guidelines (PVS1 + PM2 + PM3). The second variant, NM_000553.4 c.1270-2A>T, is a novel splice-site mutation from the maternal origin, and it can also be classified as pathogenic (PVS1 + PM2 + PM3; Figure 2a). In addition, several other variants were also found with uncertain significance, including variants in the \( \text{ABCC8} \) gene (NM_00035.2 exon6, c.824G>A, p.R275Q) and \( \text{APPL1} \) gene (NM_01209.2 exon19, c.1829A>G, p.N610S), which are genes responsible for maturity onset diabetes of the young 12 and maturity onset diabetes of the young 14, respectively.

Reverse transcription was carried out by ABScript II RT Mix for qPCR with gDNA Remover Kit (RK20403, ABclonal Technology Co., Ltd., Wuhan, China). The complementary deoxyribonucleic acid was amplified and sequenced using flanking primers located in exons 6–15 of the \( \text{WRN} \) gene, surprisingly confirming exon 14 skipping in the patient and partial intron 13 fragment inclusion in her mother, which was instead of exon 10 skipping (Figure 2b). Then we sequenced parts of intron 13, exon 14 and intron 14. However, only one single-nucleotide polymorphism (rs2247189, c.1720+24T>A) in intron 14 was identified with unknown significance. Thus, we could not identify the cause of the skipping of exon 14 or partial intron 13 fragment inclusion.

Metformin hydrochloride (0.5 g three times a day) and pioglitazone hydrochloride (30 mg once a day) were given instead of insulin to the patient. The patient’s compliance was poor due to the gastrointestinal reaction to metformin. After 2 months, the hemoglobin A1c was rechecked and found to be 7.8%, and the treatment was changed to linagliptin (5 mg once a day) and pioglitazone hydrochloride.

**DISCUSSION**

The present article reports a Chinese woman with WS who presented early-onset diabetes. Patients with WS have been reported in many populations, but the prevalence is high in some populations, resulting in founder effects, such as in Japan.

**Figure 1** | Physical characteristics of the patient. (a) Senile appearance with dry hair. (b) Slim limbs, but with abdominal obesity. (c) Dry and atrophic skin on the foot.
The prevalence of WS is estimated at 1:380,000–1:1,000,000, but it is seldom reported in Chinese people. There have been just 10 genetically confirmed WS cases so far, including the present case (Table 2, references in Appendix). The male : female ratio is 7:3. Most patients (7/10) presented first with skin change and sought medical advice in many different departments. It is necessary to raise awareness regarding WS among ophthalmologists and internal medicine doctors to promote early diagnosis.

Among these reported Chinese WS cases, four patients (4/10) had developed diabetes at the time of consultation, with a lower frequency than reported in the literature (55–71%). The onset age of diabetes in WS patients is generally 30–40 years. However, the onset age of diabetes is much earlier in the present case, which other genes and environmental factors might modify. For example, the patient’s lifestyle was unhealthy, as she especially liked drinking sugary drinks and rarely exercised. Next-generation sequencing identified two variants in diabetes-related genes with uncertain significance: the ABCC8 gene and APPL1 gene. Digenic or oligogenic causality might modify the etiology of diabetes development, which could partially explain the very early onset of diabetes in the present patient.

Clinical criteria of WS are now available at the International Registry of Werner Syndrome (www.wernersyndrome.org), and new diagnostic criteria have been revised according to clinical experience with Japanese cases of WS, including six cardinal signs and symptoms (onset >10 years-of-age until 40 years-of-age): progeroid changes of hair, cataract, changes of skin, soft-tissue calcification, bird-like face, abnormal voice, as well as seven further signs and symptoms, including abnormal glucose and/or lipid metabolism, deformation and abnormality of the bone, hypogonadism, and so on. Only one of the 10 Chinese patients reached the confirmed diagnosis, and the rest were suspected, suggesting the importance of genetic diagnosis. According to Human Gene Mutation Database Professional 2020.4, 95 mutations of WRN gene-causing WS have been recorded, most of them are predicted to result in a protein truncation, resulting

Table 1 | Laboratory investigations

| Test          | At diagnosis | Follow up (2 months) | Normal values |
|---------------|--------------|----------------------|---------------|
|               | Fasting      | 30 min after OGTT   | 60 min after OGTT | 120 min after OGTT | Fasting |
| PG (mmol/L)   | 7.84         | 13.18                | 18.17          | 11.56          | 6.82 |
| INS (mIU/L)   | 25.33        | 45.76                | 84.64          | 133.70         | 30.07 |
| CP (pmol/L)   | 1,379.4      | 1,729.8              | 2,853.2        | 4,098.3        | 1,495.0 |
| HbA1c (%)     | 8.6          | 7.8                  | 4.4–6          |
| LDL-c (mmol/L)| 2.13         | 2.47                 | 0–3.64         |
| TC (mmol/L)   | 3.54         | 3.72                 | 0–5.72         |
| TG (mmol/L)   | 1.72         | 0.78                 | 0–1.7          |
| HDL-c (mmol/L)| 0.94         | 0.95                 | 0.91–1.92      |
| UA (µmol/L)   | 266          | 258                  | 155–357        |
| TSH (mIU/L)   | 4.7195       | –                    | 0.35–4.94      |
| fT4 (pmol/L)  | 11.94        | –                    | 9.01–19.05     |
| fT3 (pmol/L)  | 5.04         | –                    | 2.63–5.7       |
| TRAb (IU/L)   | 0.42         | –                    | 0–1.75         |
| GAD (IU/mL)   | 9.16         | –                    | 0–1.7          |
| IAA (IU/mL)   | 4.96         | –                    | 0.41–20        |
| LAC (mg/dl)   | 17.4         | –                    | 4.5–198        |
| E2 (pmol/L)   | 322.7        | –                    | 45.40–854.00   |
| T (nmol/L)    | 0.78         | –                    | 0.69–253       |
| FT (pmol/L)   | 9.89         | –                    | 0.77–3303      |
| LH (mIU/mL)   | 2.84         | –                    | 1.1–116        |
| FSH (mIU/mL)  | 1.64         | –                    | 2.8–113        |
| AND (nmol/L)  | 13.40        | –                    | 1.0–115        |
| DHEA (µmol/L)| 4.97         | –                    | 0.95–1167      |
| SHBG (nmol/L)| 10.30        | –                    | 18–144         |
| Urine ketone  | (–)          | (–)                  | (–)            |

AND, androstenedione; CP, serum C peptide; DHEA, dehydroepiandrosterone; E2, estradiol; FSH, follicle-stimulating hormone; FT, free testosterone; fT3, free triiodothyronine; fT4, free thyroxine; GAD, glutamic acid decarboxylase; HbA1c, hemoglobin A1c; HDL-c, high density lipoprotein cholesterol; IAA, insulin autoantibody; INS, serum insulin; LAC, lactic acid; LDL-c, low density lipoprotein cholesterol; LH, luteinizing hormone; PG, plasma glucose; SHBG, sex-hormone binding globulin; T, testosterone; TC, total cholesterol; TG, triglyceride; TRAb, TSH receptor antibody; TSH, thyrotropin-releasing hormone; UA, uric acid.
in nonsense-mediated decay of mutant messenger ribonucleic acids and/or functionally null protein due to truncations of C-terminal nuclear localization signals. The most common mutations in Japanese patients are c.3139-1 G>C (50.4%) and c.1105 C>T (17.5%)7, where the most common mutation in non-Japanese patients is c.1105 C>T (18.6%)8, suggesting that c.1105 C>T (rs17847577) is a hotspot mutation across ethnic groups. These two mutations have also been found in two Chinese cases of WS separately, but no hotspot mutation has been implied among Chinese WS patients, which might require more cases to be found.

Initially, the variants of the WRN gene found in the present case were both believed to result in protein truncations. The first variant, c.3020delG from the paternal origin, leads to a premature stop codon downstream, yielding a truncated protein (p.Gly1007AlafsTer16). This variant was previously reported in another Chinese WS patient5. The second novel splice site variant, c.1270-2A>T, in intron 9, is predicted to cause exon 10 deletion. However, reverse transcription polymerase chain reaction showed no skipping of exon 10, but a surprising skipping of exon 14 or inclusion of intron 13 fragment. We further sequenced the whole intron 13, exon 14 and intron 14, and only one single-nucleotide polymorphism (rs2247189, c.1720+24T>A) in intron 14 was identified with unknown significance. It is challenging to elucidate why acceptor splice site mutation of one exon leads to a distant exon skipping. Still, it underlines the importance of reverse transcription polymerase chain reaction sequencing for the confirmation of suspected splice site mutations. Similarly, an instance of exon skipping not associated with splice acceptor or donor sites mutation was found in WS patients, suggesting a leaky deep intronic mutation9.

Figure 2 | Pedigree of the proband and genetic analysis of the WRN gene. (a) Pedigree of the relatives with Werner syndrome. Males and females are indicated by squares and circles, respectively. Filled symbols indicate an affected individual. Half-filled symbols indicate heterozygous carriers. The proband is indicated by a black arrow. Electropherogram of the WRN gene sequence shows two heterozygous variants. The first one is c.3020delG from the paternal origin, and the second variant, c.1270-2A>T, is a novel splice-site mutation from the maternal origin. (b) The complementary deoxyribonucleic acid was amplified and sequenced using flanking primers located in exons 6–15 of WRN, surprisingly confirming exon 14 skipping in the patient and partial intron 13 fragment inclusion (pink) in her mother, instead of exon 10 skipping. There was no mutation in intron 13, exon 14 and intron 14, except one intron variant c.1720+24T>A (blue) in intron 14 with unknown significance.
Table 2 | Summary of all Chinese genetically confirmed WS in the literature

| Reported department | P1 Dermatology | P2 Orthopedics | P3 Ophthalmology | P4 Endocrinology | P5 Neurosurgery | P6 Orthopedics | P7 Rheumatology | P8 Dermatology | P9 Neurology | P10 Endocrinology | 2020 Survey in Japan | 2020 Survey in Japan |
|---------------------|----------------|----------------|-------------------|------------------|----------------|----------------|----------------|----------------|-------------|-------------------|---------------------|---------------------|
| Diagnosis age (years) | 31 | 38 | 26 | 40 | 30 | 41 | 36 | 22 | 31 | 18 | 24.5 ± 7.3 | 42.5 ± 8.6 |
| Sex | Male | Male | Male | Female | Female | Male | Male | Male | Male | Female | Male (70%) | Male (55%) |
| Bodyweight (kg) | 27 | N.M. | 40 | 32 | 46 | 42 | 498 | NM | 525 | 41 | 46.8 ± 8.0 | 441 ± 9.5 |
| Height (cm) | 154 | N.M. | 150 | 147 | N.M. | 150 | 161 | 165 | 163 | 163 | 163.0 ± 6.7 | 154.0 ± 10.7 |
| BMI (kg/m²) | 11.4 | N.M. | 17.8 | 148 | N.M. | 187 | 192 | N.M. | 198 | 154 | 176 ± 28 | 185 ± 3.1 |
| Cardinal signs and symptoms | Progeroid changes of hair | Yes | Yes | Yes | Yes | Yes | N.M. | Yes | No | Yes | 87.5% (7/8) | 97.5% |
| Cataract | Yes | N.M. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 100% (8/8) | 100% |
| Changes of skin, Intractable skin ulcers | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 100% (10/10) | 97.5% |
| Soft-tissue calcification | Yes | N.M. | Yes | N.M. | N.M. | N.M. | N.M. | N.M. | No | Yes | 75% (3/4) | 87.5% |
| Bird-like face | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | 90% (9/10) | 90% |
| Abnormal voice | Yes | Yes | N.M. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 88.9% (8/9) | 87.5% |
| Other signs and symptoms | Abnormal glucose and/or lipid metabolism | No | N.M. | N.M. | Yes | N.M. | Yes | Yes | N.M. | No | Yes | 40% (DM) | 67.5% (DM/IGT) |
| Deformation and abnormality of the bone | Yes | N.M. | N.M. | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 87.5% (7/8) | NE |
| Malignant tumors | N.M. | N.M. | N.M. | N.M. | Yes | N.M. | N.M. | N.M. | N.M. | No | NE | 20% |
| Parental consanguinity | No | Yes | Yes | No | N.M. | Yes | No | N.M. | No | Yes | 50% (4/8) | 20.7% |
| Premature atherosclerosis | N.M. | N.M. | N.M. | N.M. | N.M. | N.M. | N.M. | N.M. | No | NE | 17.5% |
| Hypogonadism | Yes | N.M. | N.M. | Yes | N.M. | Yes | Yes | N.M. | No | Yes | 50% | 75% (6/8) |
| Short stature and low body weight | Yes | N.M. | Yes | Yes | N.M. | Yes | Yes | N.M. | No | Yes | NE | NE |
| Diagnosis based on signs and symptoms | Confirmed | Suspected | Suspected | Suspected | Suspected | Suspected | Suspected | Suspected | Suspected | Suspected | -- |
| Gene testing | Homozygous, c.1105C>T and c.1194delA | Homozygous, c.3020delG | Homozygous, c.3460_3461insTGTG | Compound heterozygous, c.3019delG and c.1270-2A>T | Homozygous, c.3139-1G>C and c.1960C>T | Compound heterozygous, c.3000delG and c.1270-2A>T | Homozygous, c.2229_2230delAG and c.3019delG | Compound heterozygous, c.1662G>C and c.3139-1G>C | Homozygous, c.3139-1G>C and c.1960C>T | Compound heterozygous, c.3000delG and c.1270-2A>T | -- |

DM, diabetes mellitus; IGT, impaired glucose tolerance; hot spot mutations in Japanese are indicated in bold; NE, not evaluated; N.M, not mentioned.
reminds clinicians that when young diabetes patients are encountered, if they are accompanied by premature aging, attention should be paid to identifying the possibility of WS based on diagnostic criteria.

**ACKNOWLEDGMENTS**
We thank our patient and her family members who agreed to participate in this study. This research was supported by the National Key Research and Development Program of China (2018YFC1313900, 2018YFC1313901).

**DISCLOSURE**
The authors declare no conflict of interest.

**REFERENCES**
1. Oshima J, Sidorova JM, Monnat RJ Jr. Werner syndrome: clinical features, pathogenesis and potential therapeutic interventions. *Ageing Res Rev* 2017; 33: 105–114.
2. Huang S, Lee L, Hanson NB, et al. The spectrum of WRN mutations in Werner syndrome patients. *Hum Mutat* 2006; 27: 558–567.
3. Takemoto M, Kubota Y, Taniguchi T, et al. Management guideline for Werner syndrome 2020. 3. Diabetes associated with Werner syndrome. *Geriatr Gerontol Int* 2021; 21: 142–145.
4. Takemoto M, Mori S, Kuzuya M, et al. Diagnostic criteria for Werner syndrome based on Japanese nationwide epidemiological survey. *Geriatr Gerontol Int* 2013; 13: 475–481.
5. Zhao N, Hao F, Qu T, et al. A novel mutation of the WRN gene in a Chinese patient with Werner syndrome. *Clin Exp Dermatol* 2008; 33: 278–281.
6. Koshizaka M, Maezawa Y, Maeda Y, et al. Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan. *Aging* 2020; 12: 24940–24956.
7. Yamaga M, Takemoto M, Takada-Watanabe A, et al. Recent trends in WRN gene mutation patterns in individuals with Werner syndrome. *J Am Geriatr Soc* 2017; 65: 1853–1856.
8. Yokote K, Chanprasert S, Lee L, et al. WRN mutation update: mutation spectrum, patient registries, and translational prospects. *Hum Mutat* 2017; 38: 7–15.
9. Friedrich K, Lee L, Leistritz DF, et al. WRN mutations in Werner syndrome patients: genomic rearrangements, unusual intronic mutations and ethnic-specific alterations. *Hum Genet* 2010; 128: 103–111.
10. Kitamoto T, Takemoto M, Fujimoto M, et al. Sitagliptin successfully ameliorates glycemic control in Werner syndrome with diabetes. *Diabetes Care* 2012; 35: e83.
11. Ide S, Yamamoto M, Takemoto M, et al. Improved glycemic control and vascular function and reduction of abdominal fat accumulation with liraglutide in a case of Werner syndrome with diabetes mellitus. *J Am Geriatr Soc* 2016; 64: 687–688.

**APPENDIX**

**REFERENCES OF CHINESE GENETICALLY CONFIRMED WERNER SYNDROME IN TABLE 2**

| Number | Reference |
|--------|-----------|
| P1     | [1]       |
| P2     | [2]       |
| P3     | [3]       |
| P4     | [4]       |
| P5     | [5]       |
| P6     | [6] (In Chinese) |
| P7     | [7] (In Chinese) |
| P8     | [8] (In Chinese) |
| P9     | [9] (In Chinese) |
| P10    | This article |

**REFERENCES**
1. Zhao N, Hao F, Qu T, et al. A novel mutation of the WRN gene in a Chinese patient with Werner syndrome. *Clin Exp Dermatol* 2008; 33: 278–281.
2. Wu PF, Jin JY, Li JJ, et al. A novel splice-site mutation of WRN (c.IVS28+2T>C) identified in a consanguineous family with Werner syndrome. * Mol Med Rep* 2017; 15: 3735–3738.
3. Chen CL, Yang JS, Zhang X, et al. A case report of Werner’s syndrome with bilateral juvenile cataracts. *BMCM Ophthalmol* 2018; 18: 199.
4. Li H, Yang M, Shen H, et al. Severe metabolic disorders coexisting with Werner syndrome: a case report. *Endocr J* 2021; 68: 261–267.
5. Hao S, Feng J, Zhang LW, et al. Rapid recurrence of petroclival meningioma in Werner syndrome: case report. *Clin Neurol Neurosurg* 2011; 113: 795–797.
6. Li珊珊，费锦萍，项守奎，et al. 中年男性:早衰-性腺功能减退-白内障. 中华骨质疏松和骨矿盐疾病杂志 2016; 9: 308–313.
7. Li S, Fei JP, Xiang SK, et al. Middle aged male: premature aging-hypogonadism-cataract. *Chin J Osteoporos Bone Mineral Dis* 2016; 9: 308–313.
7. Kong X, Wang Y, Ye B, Zhou HQ. A case of Werner syndrome mimicking scleroderma. Chin J Rheumatol 2019; 23: 326–328.

8. Zhou K, Zhu M, Hong D. Face and distal limb atrophy with skin hardening and tanning for 15 years in a young man – progeroid syndrome. Chin J Neuropsychiatr Dis 2020; 46: 509–512.

9. Charbati H, Wang RR, Ma DL, Zhang X. A case of Werner syndrome and its accurate diagnosis. Chin J Dermatol 2020; 53: 738–740.